This study comprising of 4042 vaccine population found that the use of an precise protocol for the identification and management of people prone to allergic reactions to the SARS151 CoV-2 vaccine can permit safe vaccination in possibly high risk people, consequently coping reluctance due to vaccine in allergy sufferers.

To describe the allergy work-up protocol executed for the vaccination campaign, promoting safe vaccination in large population.

Past alleged allergies linked with drug or vaccine, and consequent teleconsultation and allergometric tests for polyethylene glycol (PEG) and Polysorbate 80 (PS80) were presented in a self-report. A desensitizing protocol of vaccine administration was used to patients sensitized only to PS80, and to those with a suspect allergic reaction following the initial dose.

Out of 4042 vaccine population, 10.2% (414) have been screened: only 1 patient was found allergic to PEG and hence, dismissed from the vaccination. Another patient was allergic to PS80 only and safely vaccinated using the desensitizing protocol. 7 subjects without a allergic disease in the past suffered suspect hypersensitivity reactions to the initial dose: 1 of them was allergic to PEG and was dismissed from the second dose, whereas the others were successful in completing the vaccination safely using desensitizing protocol.

The use of meticulous allergological risk-assessment protocol can significantly decrease the number of patients who would have eluded COVID-19 vaccination for their allergies. It can also help in effective identification and management of atypical patients sensitized to PEGs and/or PS80.